OmniAb (OABI) Expected to Announce Quarterly Earnings on Wednesday

Key Points

• OmniAb is expected to release its Q2 2025 earnings on August 6th, with analysts predicting a loss of ($0.15) per share and revenue of $5.33 million.
• The company's shares traded at $2.01 on Wednesday, showing a significant fluctuation with a 12-month low of $1.22 and high of $4.95.
• Two directors recently bought shares at prices below current levels, indicating continued insider confidence, with purchases totaling approximately $130,100.

OmniAb (NASDAQ:OABI - Get Free Report) is projected to post its Q2 2025 quarterly earnings results after the market closes on Wednesday, August 6th. Analysts expect the company to announce earnings of ($0.15) per share and revenue of $5.33 million for the quarter. OmniAb has set its FY 2025 guidance at EPS.

OmniAb (NASDAQ:OABI - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.17) earnings per share for the quarter, meeting the consensus estimate of ($0.17). The business had revenue of $4.15 million during the quarter, compared to analyst estimates of $4.49 million. OmniAb had a negative return on equity of 21.37% and a negative net margin of 229.11%. On average, analysts expect OmniAb to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

OmniAb Price Performance

Shares of OmniAb stock opened at $1.91 on Monday. The stock's fifty day moving average is $1.76 and its 200-day moving average is $2.30. OmniAb has a 12-month low of $1.22 and a 12-month high of $4.87. The firm has a market capitalization of $233.29 million, a PE ratio of -3.29 and a beta of 0.16.

Insider Buying and Selling

In related news, Director John L. Higgins bought 65,000 shares of the company's stock in a transaction dated Monday, May 12th. The stock was acquired at an average cost of $1.44 per share, with a total value of $93,600.00. Following the acquisition, the director owned 2,831,887 shares in the company, valued at approximately $4,077,917.28. This represents a 2.35% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Steven Love bought 25,000 shares of the company's stock in a transaction dated Wednesday, May 14th. The stock was bought at an average cost of $1.46 per share, with a total value of $36,500.00. Following the completion of the acquisition, the director owned 38,333 shares in the company, valued at $55,966.18. This represents a 187.50% increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 8.60% of the company's stock.

Hedge Funds Weigh In On OmniAb

A hedge fund recently bought a new stake in OmniAb stock. AQR Capital Management LLC purchased a new stake in shares of OmniAb, Inc. (NASDAQ:OABI - Free Report) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 10,271 shares of the company's stock, valued at approximately $25,000. 72.08% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, Benchmark reiterated a "buy" rating and issued a $6.00 price objective on shares of OmniAb in a research report on Monday, May 12th.

About OmniAb

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.